MCL1 and acute myeloid leukemia: In conclusion, our study presents a modular approach to designing BH3 mimetics for AML, leveraging ncAAs and targeted motif engineering to achieve dual inhibition of MCL‐1 and BCL‐xL, effectively addressing Venetoclax‐associated resistance mechanisms.